share_log

贝莱德:当前医疗保健估值十分有吸引力

BlackRock: Current healthcare valuations are very attractive

富途資訊 ·  Mar 26, 2021 10:47

Standing at the beginning of 2021, how to look forward to the investment opportunities and risks of this year's health care sector? Recently, Fu Tu Information conducted an in-depth exchange with Blackrock, one of the largest asset management groups in the world, and Blackrock's natural resources research team gave an answer to the above questions.

The current valuation of health care is very attractive.

[Futu Information]: how do you view the valuation level of the health care sector?

[Blackrock Health Medical Research team]The current transaction price in the health care industry is one standard deviation lower than its long-term average, and we believe that the current valuation is a very attractive entry point for the health care industry.

In addition, we believe that health care can provide long-term growth opportunities and may provide lasting returns when economic growth slows. As we have seen in the current economic slowdown, one of the defensive drivers of the industry is the inflexibility of market demand for medical products and services, that is, there is a certain rigid demand for medical products and services at all times, which has nothing to do with stock market performance or economic growth.

Second, excited about the development of the medical industry in emerging markets in recent years

[rich Road Information]:How do you view the investment opportunities in the health care industry in emerging markets such as China and India? If you ranked the investment opportunities by region from big to small, how would you rank them?

[Blackrock Health Medical Investment and Research Group]: we are excited about the development of the medical industry in emerging markets in recent years. With the attention and investment in R & D, medical companies in emerging markets have made great progress in product innovation. For example, some contract research organizations (Contract Research Organization, CRO) and biotechnology companies in China.

India also has a good market share in many traditional pharmaceuticals. We attach more importance to the fundamentals and potential of each company.

Data source: Blackrock, as of February 19, 2021. The above data are for reference only and can be changed. There is no guarantee that any predictions made will be realized.

Material disclosure

This document was prepared by Blackrock and shall not be used as a forecast, research or investment advice, nor shall it constitute advice, solicitation or persuasion to buy or sell any securities or to adopt any investment strategy. The opinions of this article were published on February 19, 2021 and are subject to change in response to subsequent changes in conditions. The information and opinions contained in this document are taken from exclusive and non-exclusive sources that Blackrock considers reliable and do not necessarily cover all data and cannot guarantee their accuracy. Therefore, there is no guarantee of its accuracy or reliability, and Blackrock and his staff, employees or agents will not be responsible for any other forms of errors and omissions (including liability to any person for negligence). This document may contain "forward-looking" information that is not based solely on past information. The relevant information may cover, among other things, projections and forecasts. There is no guarantee that any predictions made will be fulfilled. It is up to the reader to decide whether or not to rely on the information provided in this document.

In Hong Kong, this document was published by Blackrock Asset Management North Asia Limited and has not been reviewed by the Hong Kong Securities and Futures Commission.

This data is compiled for reference only and does not constitute or rely on as financial, accounting, legal or tax advice. You should consult your consultant on such issues. Blackrock does not guarantee the applicability or potential value of any particular investment. Investment involves risks, including loss principal, and past performance does not indicate future performance. There is no guarantee that the value of the investment and its income may rise or fall. You may not be able to get back the original investment amount. Changes in the exchange rate may lead to repeated fluctuations in the value of investment. International investment involves risks, including those related to foreign currencies, limited liquidity, less government regulation, and large fluctuations due to adverse political, economic or other adverse factors. Investments in emerging or developing markets or smaller capital markets tend to increase these risks.

©2021 BlackRock, Inc. copyright. BlackRock ®is a registered trademark of BlackRock, Inc., or its subsidiaries in the United States and elsewhere. Any other trademarks belong to their respective owners.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment